Experienced in Polymorphous Low Grade Adenocarcinoma

Dr. Solmaz Sahebjam

Oncology
Johns Hopkins University
5255 Loughboro Rd Nw, Sibley Memorial Hospital, 
Washington, DC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Polymorphous Low Grade Adenocarcinoma
Johns Hopkins University
5255 Loughboro Rd Nw, Sibley Memorial Hospital, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Solmaz Sahebjam is an Oncologist in Washington, Washington, D.c.. Dr. Sahebjam is rated as an Experienced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. Her top areas of expertise are Glioma, Brain Tumor, Glioblastoma, Astrocytoma, and Awake Craniotomy. Dr. Sahebjam is currently accepting new patients.

Her clinical research consists of co-authoring 80 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Sibley Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
5255 Loughboro Rd Nw, Sibley Memorial Hospital, Washington, DC 20016
Other Locations
JOHNS HOPKINS UNIVERSITY
8600 Old Georgetown Rd, Bethesda, MD 20814

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: OBT076
Study Phase: Phase 1
A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Vorinostat, Temozolomide
Study Phase: Phase 1
Phase IB Study of Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
Phase IB Study of Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
Enrollment Status: Completed
Publish Date: September 22, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Radiation, Drug
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Bevacizumab, Cediranib, Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Telaglenastat Hydrochloride, Temozolomide
Study Phase: Phase 1
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Radiation, Drug
Study Drugs: Pembrolizumab, Bevacizumab
Study Phase: Phase 1
A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy
A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy
Enrollment Status: Terminated
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Topotecan
Study Phase: Early Phase 1
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: IRX-2, Nivolumab
Study Phase: Phase 1
Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Bevacizumab, Ipilimumab
Study Phase: Phase 1
A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Drug
Study Drugs: Trametinib, Sorafenib
Study Phase: Phase 1
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
Enrollment Status: Terminated
Publish Date: February 04, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 1
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 17 Less Clinical Trials

80 Total Publications

Imaging progression after radiotherapy for IDH mutant low-grade glioma: Sometimes it is best to stay calm and stay the course.
Imaging progression after radiotherapy for IDH mutant low-grade glioma: Sometimes it is best to stay calm and stay the course.
Journal: Neuro-oncology practice
Published: August 15, 2025
Similar Doctors
Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. David Sidransky
Oncology | Otolaryngology
Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. David Sidransky
Oncology | Otolaryngology
720 Rutland Ave, 
Baltimore, MD 
 (37.3 miles away)
410-502-5153
Languages Spoken:
English
See accepted insurances

David Sidransky is an Oncologist and an Otolaryngologist in Baltimore, Maryland. Dr. Sidransky is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adenoid Cystic Carcinoma, Salivary Gland Tumors, and Polymorphous Low Grade Adenocarcinoma.

Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Tanguy Y. Seiwert
Oncology | Hematology
Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Tanguy Y. Seiwert
Oncology | Hematology

Johns Hopkins University

5755 Cedar Ln, 
Columbia, MD 
 (22.5 miles away)
410-740-7544
Languages Spoken:
English, French, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Tanguy Seiwert is an Oncologist and a Hematologist in Columbia, Maryland. Dr. Seiwert is rated as an Advanced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Glioma, Laryngeal Cancer, Tongue Cancer, Oral Squamous Cell Carcinoma, and Gastrostomy. Dr. Seiwert is currently accepting new patients.

Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Karim Boudadi
Oncology | Hematology
Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Karim Boudadi
Oncology | Hematology

Johns Hopkins University

8600 Old Georgetown Rd, 
Bethesda, MD 
 (4.2 miles away)
301-896-3100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Karim Boudadi is an Oncologist and a Hematologist in Bethesda, Maryland. Dr. Boudadi is rated as an Advanced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Glioma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, Gastrointestinal Stromal Tumor, and Prostatectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sahebjam's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile